Filing Flows › Amneal Pharmaceuticals (AMRX) › Q3 2026 › vs Q3 2025
Amneal Pharmaceuticals (AMRX) Q3 2026 vs Q3 2025 (year over year)
Amneal Pharmaceuticals's revenue rose $78.2M (+10%) from $785M in Q3 2025 to $863M in Q3 2026. Gross margin 38.7% against 34.9% (+3.8 pts).
Amneal Pharmaceuticals, Q3 2026: revenue $863M (+10% year over year), operating margin 11.1%, net earnings $12.3M, operating cash flow $98.3M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 38.7% | 34.9% | +3.8 pts |
| Operating margin | 11.1% | 9.0% | +2.1 pts |
| Net margin | 1.4% | 2.3% | -0.9 pts |
| Free cash flow margin | 7.7% | 13.5% | -5.8 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $863M | $785M | $78.2M | +10% |
| Gross profit | $334M | $274M | $60.1M | +22% |
| Cost of revenue | $529M | $511M | $18.0M | +4% |
| Operating profit | $95.4M | $70.3M | $25.1M | +36% |
| Operating expenses | $239M | $204M | $35.1M | +17% |
| Pre-tax earnings | $15.1M | −$5.2M | $20.3M | — |
| Other expense, net | $80.4M | $75.6M | $4.8M | +6% |
| Research & development | $68.4M | $63.4M | $5.0M | +8% |
| SG&A | $140M | $138M | $1.8M | +1% |
| Other operating costs | $30.7M | $2.5M | $28.2M | 12× |
| Net earnings | $12.3M | $18.1M | −$5.8M | -32% |
| Income tax | $2.8M | −$23.4M | $26.1M | — |
| Share-based compensation | $10.5M | $8.2M | $2.3M | +28% |
| Working capital & other | $75.5M | $92.1M | −$16.6M | -18% |
| Operating cash flow | $98.3M | $118M | −$20.2M | -17% |
| Free cash flow (OCF − capex) | $66.5M | $106M | −$39.6M | -37% |
| Capital expenditures | $31.8M | $12.3M | $19.5M | +158% |
Questions
How much did Amneal Pharmaceuticals's revenue grow year over year in Q3 2026?
Amneal Pharmaceuticals's revenue rose $78.2M (+10%) from $785M in Q3 2025 to $863M in Q3 2026. Gross margin 38.7% against 34.9% (+3.8 pts).